Breast cancer bone metastasis with abecyclidine is effective, can effectively extend the survival of patients. Abciximab belongs to the CDK4/6 inhibitor class of targeted drugs, the drug can selectively act in the cell cycle protein-dependent kinase 4/6, so that the cell cycle control is restored, blocking tumor cell proliferation, inhibiting tumor growth, stabilizing the patient’s condition. It is mainly used in the treatment of HR+, HER2-positive advanced metastatic breast cancer, and the overall therapeutic effect is still good, which can effectively prolong the survival of patients and improve their quality of life. However, abecyclidine is not suitable for all breast cancer patients, and it needs to be used only by those who meet the requirements of a comprehensive genetic examination; and during the period of using the drug, patients may have adverse reactions such as loss of appetite, vomiting, regurgitation, and skin rashes, which are generally mild and do not require special treatment; if the situation is serious, then it is necessary to use the drug for a short period of time. The therapeutic effect of Abecyclis on breast cancer is still good, but it should be used according to the doctor’s instructions, and it is not recommended to be used by lactating or pregnant women.